This segment focuses on the key efficacy data on progression-free survival, response rates, and duration of response from MARIPOSA-2.
Multidisciplinary Team Discusses Practical Treatment Options in NSCLC
Experts at City of Hope explore innovative immunotherapy strategies for non-small cell lung cancer, highlighting efficacy and toxicity management in treatment.
Integrating Dato-DXd Into Early-Line EGFR-Mutant NSCLC Management
Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.
Evaluating the Top EGFR+ NSCLC Treatment Combinations
Experts discuss evolving therapies for EGFR-mutated metastatic NSCLC, comparing combination regimens and their impact on patient outcomes.
Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting
Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.
TTFields Earns Japanese Approval in Unresectable Advanced/Recurrent NSCLC
The decision from the Ministry of Health, Labour and Welfare was supported by phase 3 LUNAR trial results showing an OS benefit with Optune Lua in NSCLC.
Ateganosine Combo Exhibits Favorable Efficacy vs SOC in Advanced NSCLC
Ateganosine plus cemiplimab was well tolerated in patients with heavily pretreated advanced NSCLC, with most adverse effects grades 1/2 in severity.